MSFP
RIGL icon

Mark Sheptoff Financial Planning’s Rigel Pharmaceuticals RIGL Stock Holding History

Mark Sheptoff Financial Planning’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.02K Hold
250
– – ﹤0.01% 386
2025
Q4 		$10.7K Buy
+250
New +$9.42K 0.01% 346

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mark Sheptoff Financial Planning's RIGL Position: Q1 2026 in Review

Mark Sheptoff Financial Planning held its Rigel Pharmaceuticals (RIGL) position steady in Q1 2026 at 250 shares worth $7.02K. The position accounts for ﹤0.01% of the portfolio, ranked #386.

Mark Sheptoff Financial Planning first reported a position in RIGL in Q4 2025 and has held it in 2 quarters since. The position peaked at $10.7K in Q4 2025. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.

  • Mark Sheptoff Financial Planning held 250 shares of Rigel Pharmaceuticals worth $7.02K as of Q1 2026.
  • Mark Sheptoff Financial Planning left its Rigel Pharmaceuticals share count unchanged in Q1 2026.
  • Rigel Pharmaceuticals made up ﹤0.01% of Mark Sheptoff Financial Planning's portfolio in Q1 2026, its #386 holding.
  • Mark Sheptoff Financial Planning first reported a position in Rigel Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Mark Sheptoff Financial Planning's Rigel Pharmaceuticals position peaked at $10.7K in Q4 2025.
  • 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.

Based on Mark Sheptoff Financial Planning's 13F filing for Q1 2026, filed 11 May 2026.